"trastuzumab refractory her2 positive" trang 4 - tải miễn phí từ tailieunhanh
Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: A report of two cases

Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: A report of two cases
5    49    1
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
12    34    1
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
12    44    1
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
14    31    1
The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

The SystHERs registry: An observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer
11    45    1
MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway
13    54    1
Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy
16    28    1
Heparan sulfate mediates trastuzumab effect in breast cancer cells

Heparan sulfate mediates trastuzumab effect in breast cancer cells
13    32    1
Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab

Heavy chain dimers stabilized by disulfide bonds are required to promote in vitro assembly of trastuzumab
9    43    1
Ảnh hưởng của Trastuzumab lên chức năng cơ tim ở bệnh nhân ung thư vú

Ảnh hưởng của Trastuzumab lên chức năng cơ tim ở bệnh nhân ung thư vú
7    27    1
Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)

Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)
12    61    1
Clinical characteristics and disease outcomes in ER+ breast cancer: A comparison between HER2+ patients treated with trastuzumab and HER2- patients

Clinical characteristics and disease outcomes in ER+ breast cancer: A comparison between HER2+ patients treated with trastuzumab and HER2- patients
10    44    1
Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer
8    55    1
Kết quả điều trị bổ trợ trước phác đồ hóa chất kết hợp trastuzumab và pertuzumab trên ung thư vú có HER2-neu dương tính

Kết quả điều trị bổ trợ trước phác đồ hóa chất kết hợp trastuzumab và pertuzumab trên ung thư vú có HER2-neu dương tính
6    49    1
Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies— the role of HAS2, SHB and HBEGF

Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies— the role of HAS2, SHB and HBEGF
17    11    1
The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: A phase II, multicenter, single-arm study (SYSUCC-005)

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: A phase II, multicenter, single-arm study (SYSUCC-005)
8    16    1
Kết quả hóa trị bổ trợ phác đồ Docetaxel – Carboplatin – Trastuzumab trên bệnh nhân ung thư vú có Her2/neu dương tính

Kết quả hóa trị bổ trợ phác đồ Docetaxel – Carboplatin – Trastuzumab trên bệnh nhân ung thư vú có Her2/neu dương tính
6    30    1
Change of charge variant composition of trastuzumab upon stressing at physiological conditions

Change of charge variant composition of trastuzumab upon stressing at physiological conditions
9    9    1
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer

HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer
10    1    1
Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
10    8    1